Cadenza Bio

United States - Oklahoma City

• 18/12/2023
• Seed
• $2,440,000

Cadenza Bio, Inc. was founded in 2022 to accelerate and support the development of a series of novel, non-steroidal, highly selective compounds targeting Estrogen Receptor β (ERβ). Our patented and patent-pending compounds have shown therapeutic efficacy in preclinical animal models of Multiple Sclerosis and Endometriosis.

Our goal goes beyond incremental improvements. We are dedicated to breaking the cycle of disease and, in doing so, transforming lives. We aim not only to alleviate symptoms but to halt progression, promote repair, and restore quality of life to enable total activity, empowering patients to regain control over their health.

Related People

Carol CurtisCo Founder

United States - Oklahoma City, Oklahoma

Knowledge and experience in technology transfer, patenting and licensing of inventions, project management, early stage venture management consulting, pre-investment risk analysis/due diligence and venture capital investing.

LinkedIn https://www.linkedin.com/in/carol-curtis-phd/